Aptevo Therapeutics Inc.
$4.74
-0.3420 (-6.73%)
Join the Aptevo Therapeutics Inc. Investor Community
Get the latest news and company updates delivered straight to your inbox. Subscribe for free to stay ahead of the story and follow Aptevo Therapeutics Inc. as new developments unfold.
Company Overview
Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies through its proprietary bispecific antibody platforms, ADAPTIR® and ADAPTIR-FLEX®. The company is advancing a diverse pipeline that includes both clinical and preclinical candidates designed to harness the immune system to target hematologic and solid tumors with greater precision and safety. With a focus on innovation, Aptevo is leveraging modular antibody engineering to address areas of high unmet medical need and capture opportunities across multi-billion-dollar oncology markets.
Value Proposition
Aptevo Therapeutics (Nasdaq: APVO) offers a rare and timely opportunity for investors seeking exposure to high-impact oncology innovation. Built on the Company’s proprietary ADAPTIR® and ADAPTIR-FLEX® platforms, Aptevo is advancing a pipeline of innovative bispecific antibodies designed to precisely direct immune responses against cancer while minimizing the dose limiting toxicities often seen with similar immunotherapies.
Phase 1b/2 lead candidate, mipletamig, is being evaluated in combination with standard of care therapy for frontline acute myeloid leukemia (AML), and has shown a 90% remission rate across two trials—that outperforms standard of care alone. In the ongoing RAINIER trial. A common side effect, no cytokine release syndrome (CRS) has been reported in the current trial to date The emerging data supports mipletamig's impact on treatment outcomes in frontline AML patients who are not fit for intensive chemotherapy.
The company’s second clinical asset, ALG.APV-527, has demonstrated encouraging results in multiple solid tumors, with tumor-localized immune activation and favorable safety across multiple cancer types. These two clinical programs are complemented by a robust preclinical pipeline targeting additional billion-dollar indications, including prostate, breast, and lung cancers.
With multiple clinical readouts, regulatory milestones, and potential partnerships expected over the next 12–18 months, Aptevo is well positioned at the intersection of scientific innovation and strategic execution. For both institutional and retail investors, Aptevo offers a high-conviction small-cap biotech story with near-term momentum and long-term value creation
Investor Presentation
Investment Highlights
Multi-Billion-Dollar Opportunities
- Pipeline Molecules that specifically target oncology indications in multi-billion-dollar underserved markets
Rationally Designed Assets
- Bispecifics that are engineered for optimal immune engagement delivering enhanced efficacy, safety and precision targeting of tumors while minimizing toxicity
Derisked Clinical Candidates
- Two clinical programs showing strong safety, tolerability, and efficacy, reducing development risk and increasing the likelihood of regulatory and commercial success
Inflection Points Can Drive Stock Price
- Near-term catalysts include clinical readouts, regulatory milestones, and partnership opportunities setting up potential valuation surges as the Company progresses
Long-Term Value Creation & Scalability
- Modular platform enables efficient expansion into additional tumor types and combination therapies ensuring sustained pipeline growth and strategic partnerships
Clinical Trial Pipeline Stages
| Drug Name | Stage |
|---|---|
| APVO436 (mipletamig) +/- Venetoclax + AzacitidineDetailsMyelodysplastic syndrome, Acute myeloid leukemia, Cancer | Phase 1/2 |
| ALG.APV-527 (4-1BB x 5T4)DetailsCancer, Solid tumor/s, Pancreatic cancer, Non-small cell lung carcinoma, Breast cancer, Colorectal cancer | Phase 1 |
| ALG.APV-527 (4-1BB x 5T4)DetailsCancer, Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma, Breast cancer | Phase 1 |
Sign Up For APVO Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Aptevo Therapeutics (APVO) is a client of RedChip Companies. APVO agreed to pay RedChip Companies, Inc. a $9,000 monthly cash fee, beginning May 2025, for 6 months of investor awareness services. APVO also agreed to pay RedChip a one-time $50,000 cash fee for a 10-day national TV ad campaign aired November 18 to November 29, 2024, a one-time $45,000 cash fee for a 10-day national TV ad campaign aired December 4 to December 17, 2024, a one-time $45,000 cash fee for a 10-day national TV ad campaign aired February 17 to February 28, 2025, and a one-time $75,000 cash fee for a four-week national TV ad campaign aired in May 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.